Navigation Links
S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
Date:5/4/2011

SINGAPORE, May 4, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced the restructuring of its collaboration and option agreement with Onyx Pharmaceuticals, which was entered into in January 2009. As a result, S*BIO has regained North American and European rights to its novel JAK2 inhibitors, SB1518 and SB1578, from Onyx.  Following a successful and productive partnership with Onyx, S*BIO will now be in a position to drive the development of its lead JAK2 program independently.

Recent data from Phase 2 clinical trials of SB1518 indicated promising clinical efficacy and good tolerability for the treatment of myelofibrosis (MF), an orphan indication with high unmet medical need.  SB1518 has also demonstrated clinical benefits in patients with relapsed/refractory lymphoma. S*BIO plans to advance SB1518 and SB1578 expeditiously through clinical development, with pivotal trials for SB1518 anticipated to begin later this year.

"Consolidating North American and European rights for SB1518 and SB1578 represents a unique opportunity for S*BIO to steer the global development of these two promising products," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "Our strong relationship with Onyx has led to the successful clinical advancement of both SB1518 and SB1578.  SB1518 has now reached a critical inflection point where its future success in a highly competitive field depends on an aggressive and focused development plan. As an existing shareholder, Onyx's interests remain aligned with S*BIO's objective to maximize the value of the JAK2 program and to share in the upside potential of SB1518 and other S*BIO assets."

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around kinases and histone deacetylases (HDAC). SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008
'/>"/>

SOURCE S*BIO
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
3. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
10. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... DIEGO , July 10, 2014  RESMED INC. (NYSE: ... its fourth quarter and fiscal year ended June 30, 2014 ... Stock Exchange market close. A press release with ResMed,s results ... the company will host a webcast to discuss operating results ... to begin at 1:30 p.m. US Pacific Time and the ...
(Date:7/10/2014)... 2014  BC Technical, the largest nationwide, non-OEM provider ... Inc., a leading provider of Siemens Nuclear Medicine and ... naming BC Technical as the authorized provider of service ... and BC Technical announced today that the two companies ... as the service and systems provider for MiE,s camera ...
(Date:7/10/2014)... Ariz. , July 10, 2014   Ventana ...  Group, today announced it has entered into an agreement ... which operates as EMD Serono in the ... , to collaborate with Merck KGaA,s biopharmaceutical division on ... for an undisclosed target using Ventana,s proprietary diagnostic assays. ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS ... and the Integrated BioBank of Luxembourg (IBBL) today announced ... expand the use of the WaferGen SmartChip Real-Time PCR ... The agreement includes: The purchase ...
... BUDAPEST, HUNGARY, Dec. 16, 2010 Watson Pharmaceuticals, Inc. ... Plc ("Richter") today announced that Watson,s subsidiary, Watson Laboratories, ... PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, ... U.S. and Canada.  In European studies, Esmya™ has been ...
Cached Medicine Technology:WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 2WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 4WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 5Watson and Richter Announce Exclusive License Agreement for Esmya™ 2Watson and Richter Announce Exclusive License Agreement for Esmya™ 3Watson and Richter Announce Exclusive License Agreement for Esmya™ 4Watson and Richter Announce Exclusive License Agreement for Esmya™ 5
(Date:7/14/2014)... Downers Grove, IL (PRWEB) July 14, 2014 ... and online marketing company for mental health professionals, ... Professional Counselors Association of North Carolina (LPCANC). ... extend their online marketing solutions to LPCANC members, ... the past 7 years, we have been dedicated ...
(Date:7/14/2014)... Spine Team Texas continues ... diagnosis to treatment and recovery. Currently all physical therapists ... or training for certification in The McKenzie Method. Two ... the extensive program. , “We require certification of our ... in better outcomes for spine pain patients,” said Mark ...
(Date:7/14/2014)... New research and analysis from the national ... examines toxic ingredients in tampons, a product used ... chemicals that may be found in the product’s absorptive ... put women’s health at risk. , According to ... , the potential impact of toxic chemical exposure from ...
(Date:7/13/2014)... Save the Date for the 2014 Art & ... , BOXWOODS & BowTies “A Modern Twist on Southern Traditions” ... Women’s Board of Wolfson Children’s Hospital will host its ... their ongoing commitment to raising funds for the advancement of ... The 2014 Art & Antiques Show is a three-day show ...
(Date:7/13/2014)... 14, 2014 The special two-day sale starts ... Sublime Beauty®. Use coupon code 20SCRUB at the webstore checkout. ... who tries the Fresh Citrus Scrub falls in love with ... is a perfect little cleanser for face, but can also ... beads that help to exfoliate with pleasure, clean pores and ...
Breaking Medicine News(10 mins):Health News:TherapySites Partners With the Licensed Professional Counselors Association of North Carolina to Make Online Marketing Available to All Therapists 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 2Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 3Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 4Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 5Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 6Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 7Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 8Health News:Save the Date for the 2014 Art & Antiques Show benefiting Wolfson Children's Hospital in Jacksonville, FL 9Health News:Discover the Favorite Sublime Beauty® Citrus Scrub: Special "Two-Day Only" Sale 2
... conducted by Professor William Ledger, a fertility expert at ... of producing //a baby through in-vitro fertilisation and the ... study states that the benefits of providing free fertility ... to the government. ,He along with a ...
... is a bacteria resistant to certain antibiotics. This bacteria ... systems, especially in hospitals and nursing homes and is ... like the Netherlands, Sweden, and Norway, where MRSA has ... now facing an increase in incidence with the rates ...
... of infecting 400 Libyan children with AIDS, five Bulgarian Nurses ... //in the Court of Appellations in Tripoli. ... hospital aids made the outbreak possible since all the instruments ... that outbreak was made by them knowingly. ,Re-assessment ...
... seeking various opinions on the issue of doctors being allowed ... a ban. , In its new draft guidance, ... them that the relationship would usually be considered inappropriate. ... the guidelines acknowledge that social circumstances may demand ...
... of Medicine and colleagues finds it’s better to inform ... dizzy feel of nausea previously. ... to adversity – both subjectively and physiologically,’ said lead ... can benefit people greatly.’ ,The study, designed ...
... found in cannabis, also known as hashish or marijuana, ... it on rats //. ,Yehoshua Maor, a ... created a synthetic version of a minor cannabis constituent ... lowering blood pressure, reported science portal The News Medical. ...
Cached Medicine News:Health News:Free IVF Treatment Could Prove Beneficial to the Society And Its Economy 2Health News:Super-bug MRSA Getting Fitter And Out of Control 2Health News:Precautious Measure Help Tolerate Nausea In Patients 2Health News:Precautious Measure Help Tolerate Nausea In Patients 3
... Workstations provide comprehensive neurological monitoring in ... unit to accurately access your patients ... 15 years experience, and a long ... neurological monitoring systems have a proven ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
The Nicolet Bravo™ is a Multi-application system that can configure to meet the needs of neurophysiology department....
... system especially designed for surgical monitoring and ... channels and is equipped with two headboxes ... can be independently configured as either a ... Endeavor amplifiers are based on the Firewire ...
Medicine Products: